Ensitrelvir is a medicine used to help prevent COVID-19 after you have been around someone who has it. It is taken as a pill. It works by blocking a protein the virus needs to make copies of itself.
Every report comes from a Lived member, sent anonymously.
Have you tried Xocova (Ensitrelvir) for COVID-19?
Ensitrelvir, sold as Xocova, is a prescription antiviral pill taken to lower the chance of getting sick with COVID-19 after close contact with someone who has it. In the US it is approved for this kind of prevention, called post-exposure prophylaxis, in adults and adolescents 12 and older. It is meant for people who do not have COVID-19 yet, and it is not approved in the US to treat an infection that has already started. The approval rests on a large trial of people living in the same household as someone who had just come down with COVID-19. Most participants were vaccinated or had been infected before, so the results describe people with some existing immunity. Its protection covers only the exposure it was taken after.
To multiply, the virus that causes COVID-19 first makes long protein chains inside an infected cell. An enzyme called the main protease (also known as 3CL protease) cuts those chains into the working parts the virus needs to copy itself. Ensitrelvir binds to that enzyme and blocks it, so the virus cannot build new copies. Taken soon after exposure, this can stop a small, early infection from growing enough to cause illness. It does not act on the immune system, and it offers no lasting protection once the course is finished.
Xocova comes as 125 mg tablets. The course lasts five days: three tablets taken together on day 1, then one tablet a day on days 2 through 5. Tablets can be taken with or without food, at about the same time each day. Timing matters. The course should begin as soon as possible, and no later than 72 hours after contact with the person who has COVID-19. Before prescribing, the clinician checks whether a pregnancy is possible and reviews every medicine and supplement being taken. If a dose is missed, take it as soon as possible the same day, then take the next dose at the usual time the following day.
Side effects in the main trial were uncommon and mostly mild. Headache, diarrhea and cough each happened in fewer than 3 in 100 people, only slightly more often than with a placebo (a dummy pill). Serious allergic reactions, including anaphylaxis and swelling of the face, lips, tongue or throat (angioedema), have been reported since the medicine came into use in other countries. Stop Xocova and contact the prescriber right away for a rash or hives. Trouble breathing or swelling of the lips, tongue or throat is an emergency: call 911.
Ensitrelvir strongly blocks CYP3A, a liver enzyme that clears many other medicines from the body. Taking it alongside some of those medicines can raise their levels enough to cause serious or life-threatening effects. Examples it must not be combined with include simvastatin (a cholesterol-lowering statin), colchicine (a gout medicine) in people with kidney or liver problems, the antipsychotics pimozide and lurasidone, the sleeping pill triazolam, and ergotamine-type migraine medicines. Other medicines, such as tacrolimus or cyclosporine taken after an organ transplant, may need a dose change, a pause or closer monitoring. Because ensitrelvir stays in the body for several days, the prescriber will also say when a paused medicine can safely restart. The reverse also happens. Rifampin (an antibiotic for tuberculosis), the seizure medicines carbamazepine and phenytoin, the prostate cancer medicines apalutamide and enzalutamide, and the herbal supplement St. John's wort can lower ensitrelvir levels enough that it may not work, so they are not used together. Tell the prescriber and pharmacist about every prescription, over-the-counter medicine and supplement. In animal studies, ensitrelvir caused birth defects and pregnancy loss, so it may harm a developing baby. Pregnancy status is checked before starting, and people who could become pregnant should use effective birth control during the course and for 2 weeks after the last dose. Anyone who is or might be pregnant should tell the prescriber. Breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Most people take the full five-day course without noticing much at all. In the main trial, about 3 in 100 household contacts who took ensitrelvir developed symptomatic COVID-19 within 10 days, compared with about 9 in 100 who took a placebo. That is roughly two thirds fewer cases, or about 6 fewer illnesses for every 100 people treated. The trial counted symptomatic infections; it did not show whether Xocova prevents hospital stays or deaths. Protection is not complete, so it still makes sense to watch for symptoms and test if they appear during or after the course. COVID-19 that develops anyway is managed the same way as any other case, and a person at higher risk of severe illness should ask about treatment promptly. Once the five days are done there is no ongoing monitoring, and a new exposure later would need a new decision.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Xocova (Ensitrelvir), what you've noticed, or ask the community a question.